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Abstract
Human metastatic cutaneous melanoma has gained a well deserved reputation for its immune
responsiveness. The reason(s) remain(s) unknown. We attempted previously to characterize
several variables that may affect the relationship between tumor and host immune cells but, taken
one at the time, none yielded a convincing explanation. With explorative purposes, high-
throughput technology was applied here to portray transcriptional characteristics unique to
metastatic cutaneous melanoma that may or may not be relevant to its immunogenic potential.
Several functional signatures could be identified descriptive of immune or other biological
functions. In addition, the transcriptional profile of metastatic melanoma was compared with that
of primary renal cell cancers (RCC) identifying several genes co-coordinately expressed by the two
tumor types. Since RCC is another immune responsive tumor, commonalities between RCC and
melanoma may help untangle the enigma of their potential immune responsiveness. This purely
descriptive study provides, therefore, a map for the investigation of metastatic melanoma in future
clinical trials and at the same time may invite consideration of novel therapeutic targets.
Background
Human metastatic cutaneous melanoma relative to other
common solid tumors shares with renal cell cancer (RCC)
the well deserved reputation of being responsive to
immune manipulation [1,2]. However, the reason(s) for
this phenomenon remain(s) largely unknown [3]. Possi-
bly, metastatic cutaneous melanoma is endowed com-
pared to other tumors with a wealth of "tumor rejection"
antigens of unique immunogenic potential. Indeed, the
ease in which tumor infiltrating lymphocytes recognizing
autologous tumor cells can be isolated from melanoma
metastases suggests an extraordinary ability of melanoma
cells to elicit cognitive T cell responses [4]. In addition, the
broad repertoire of melanoma-associated antigens so far
discovered largely outnumbers that of other tumors sug-
gesting a stronger immunogenicity of this cancer [5-7].
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RCC-specific antigens described and the relative difficulty
of expanding tumor infiltrating lymphocytes from RCC
that can recognize autologous cancer cells. Yet, RCC is
somehow also responsive to immune therapy [2,8]. sug-
gesting that explanations other than solely the identity of
T cell epitopes should be considered.
We have previously shown that the microenvironment of
a subgroup of melanoma metastases expresses at the tran-
scriptional level an array of biologically active factors that
may influence both the innate and the adaptive arm of the
immune system [9]. We have also observed that subcuta-
neous melanoma metastases likely to respond to immu-
notherapy have a different genetic profile than those
unlikely to respond to therapy [10]. This genetic profile
differs particularly in expression of immunologically rele-
vant genes suggesting that melanoma metastases that
respond to therapy are conditioned to respond even
before therapy by an immunologically active environ-
ment. These pilot studies encouraged us to collect a large
series of melanoma metastases and analyze their genetic
profile to search for molecular signatures specific for this
tumor entity compared with other less immunogenic can-
cers. The lack of clinical information limited this study to
a descriptive analysis of the molecular signatures charac-
teristic of melanoma that could serve as a map for future
studies on this subject. In addition, the application of
high-throughput technology to identify transcriptional
characteristics unique to metastatic cutaneous melanoma
may define novel targets which can be employed for fur-
ther analysis. . Several signatures were identified descrip-
tive of immune or other biological functions that might
be relevant to immune responsiveness. Furthermore, a
comparison of the transcriptional profile of metastatic
melanoma with that of a library of available primary RCC
identified several genes co-coordinately expressed by the
two tumor types. Since RCC represents another immune
responsive human tumor it is possible that commonali-
ties with melanoma may reveal, in the future, the secret of
immune responsiveness. This purely descriptive study
provides, therefore, a map of markers for the investigation
of metastatic melanoma in novel clinical trials and may
invite consideration of novel therapeutic targets.
Results and Discussion
Differences between the transcriptional profile of 
melanoma metastases and other solid tumors
We first identified genes differentially expressed between
69 melanoma samples and 87 samples obtained from
available primary or metastatic solid tumors (Table 1).
RCC samples were excluded from the statistical compari-
son because this tumors share immune responsiveness
with metastatic melanoma and, therefore, were consid-
ered separately from non-immunogenic tumors. Differen-
tial expression was defined significant at a p2-value ≤
0.001 (unpaired two-tailed Student t test). This test iden-
tified 4,658 cDNA clones differentially expressed between
melanoma metastases and tumors of other histology (see
Additional file 1). Non parametric Wilcoxon test yielded
comparable results in terms of number and identity of dif-
ferentially expressed genes (data not shown). Permuta-
tion analysis strongly supported the significance of these
findings. Approximately half of the differentially
expressed clones (2,044) were up-regulated in melanoma
metastases relative to other tumors and the remaining
2,614 clones were down-regulated. Up-regulation was
defined as a positive value after subtracting the average
ratio of other tumors from that of melanoma lesions (Fig-
ure 1). Down-regulation was considered a negative value
resulting from the same formula. A large proportion of the
genes down-regulated in melanoma relative to other
tumor were lineage specific and reflected its unique
ontogeny from the neuroectoderm while the tumors stud-
ied were mostly of epithelial origin. We have previously
described the weight that ontogeny may play in balancing
the transcriptional profile of RCC [11]. Unfortunately, for
this type of analysis to be conclusive availability of
matched normal tissues is required which is not as readily
achievable in the case of melanoma due to the scattered
distribution of normal epithelial melanocytes within the
skin layers. The complete list of the 4,658 genes differen-
tially expressed by melanomas is available at http://
www.societymelanomaresearch.org
Signature-specific genes
Several signatures representing genes preferentially
expressed by melanomas were identified that could be
partially linked to specific gene functions. Those signa-
tures were segregated according to unsupervised gene rear-
rangement based on the Eisen's clustering method. The
first cluster (cluster a, Figure 1) included 76 clones of
which 63 were named corresponding to 53 genes. A sub-
set of genes in this cluster were commonly up-regulated in
melanoma and RCC including enolase 2 (neuronal γ-eno-
lase) which is a previously described serum marker of RCC
also associated with renal carcinogenesis [11-13]. Differ-
ential expression of enolase-2 between melanoma and
other cancers with the exception of RCC reached a signif-
icance of 5 × 10-7 and 1 × 10-6 for two clones representing
this gene (Student's t-test p2 value). Overall, this cluster
was enriched of genes associated with active cellular
metabolism and included only few genes of previous
known relevance to melanoma with the exception of a
member of the melanoma antigen family D (MAGED2,
Table 2 and Figure 2). Cluster b included 91 clones (72
named representing 65 distinct genes) predominantly
associated with growth regulation and apoptosis. Among
the genes included in this cluster was BNIP3L (BCL2/Ade-
novirus E1B interacting protein like-3, t-test p2-value = 2 ×Page 2 of 14
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have previously reported to be associated with the
immune responsiveness of melanoma metastases [10].
Two large and related clusters (cluster c and d) included
262 and 613 clones, respectively (112 and 296 named
corresponding respectively to 110 and 289 genes). These
clusters were characterized by a high density of unnamed
clones and by relatively low Cy5/Cy3 ratios. However, it
should be noted that these clusters may be of particular
interest because the gene expression profile was similar
between melanoma and RCC tumors suggesting that
some of these genes may conceal the enigma of immune
responsiveness. In particular, a relatively sizable sub-clus-
ter was noted with genes predominantly up-regulated in
RCC but also expressed by melanoma lesions compared
with other tumors (Blue arrow and double vertical bar,
Figure 1). Genes concomitantly up-regulated in
melanoma and RCC will be separately discussed later,
however, it is important to note that this cluster included
JAK-1 (t-test p2-value = 2 × 10-5) that was previously also
reported in association with melanoma immune respon-
siveness to interleukin-2-based immunotherapy [10].
JAK-1 was recently linked to the apoptotic role that inter-
leukin-24 (melanoma differentiation associated gene-7:
MDA 7) may exert on melanoma cells [14]. The following
cluster (cluster e) included 208 clones (151 named repre-
senting 143 different genes) predominantly associated
with immune function. This immune signature was
underlined by the high prevalence of expression of these
genes in samples obtained from lymph node metastases
whether from melanoma or colorectal primaries. Cluster
f integrated 129 clones (91 named representing 87 dis-
tinct genes) including a mixture of genes with disparate
functions difficult to categorize into a predominant pat-
tern. This group also included APPBP1 (amyloid β precur-
sor protein; t-test p2-value = 1 × 10-4) which was
previously reported in association with melanoma
immune responsiveness [10]. APPBP1 is a recently discov-
ered epidermal growth factor that regulates dendrite
motility and melanin release in epidermal melanocytes
and melanoma cells [15]. It is possible that some of its
functions may have an indirect effect in modulating the
immunological profile of subcutaneous metastases. Clus-
ter g included genes preferentially up-regulated in subcu-
taneous melanoma metastases known to be more
responsive to immunotherapy with interleukin-2 [16].
This cluster included 201 clones (142 named representing
132 genes). Among the genes representative of this cluster
were two classic melanoma associated genes (PRAME and
tyrosine-related protein-1; TRP-1). In a small proportion,
this cluster included a group of genes only over-expressed
in fine needle aspirates (FNA) and generally expressed by
circulating cells revealing blood contamination of FNA
material (red arrow, Figure 1). Cluster h included 131
clones (102 named representing 99 genes). Cluster I
included 222 clones (171 named identifying 155 genes)
with most of the melanoma differentiation antigens
(MDA) clustering in close proximity with the exception of
the TRP-1 already discussed in cluster g. Interestingly, this
cluster was also highly enriched of genes associated with
ribosomal function and active translation. Furthermore, it
included the melanocyte master regulator MITF (t-test p2-
value for two respective cDNA clones = 2 × 10-15 and 8 ×
10-14) which has been shown to modulate lineage survival
and melanoma cell viability through interaction with the
anti-apoptotic protein BCL2 [17]. MITF was coordinately
expressed with several genes associated with calcium and
other solute metabolism including cytochrome p450 (t-
test p2-value for two respective cDNA clones = 3 × 10-12
and 7 × 10-13) solute carrier family 7 (t-test p2-value for
two respective cDNA clones = 2 × 10-10 and 2 × 10-6), G
protein coupled receptor 56 (t-test p2-value = 2 × 10-7) and
calpain 3 (t-test p2-value = 6 × 10-15), a calcium-regulated
gene found to be highly expressed in melanoma cells [18].
Finally, cluster J included 88 clones of which the 62
named identified 58 genes.
Genes previously recognized to be associated with 
melanoma
Genes previously described to be preferentially expressed
by melanoma lesions were confirmed to be so at a very
high level of significance (Figure 2). Exceptions included
AIM-1, CXCL-1 (GRO-α), D2S448 and MAGEA1 which
are all significantly more expressed by tumors other than
melanomas. Interestingly, different types of melanoma
associated genes displayed a different pattern of expres-
sion with MDA (tyrosinase, gp100/PMel17 and MART-1/
MelanA) being co-coordinately expressed in close proxim-
ity to each other in cluster I and MAGE family genes pref-
erentially expressed in cluster d (Table 2). Cluster g
included a number of genes whose expression had been
previously associated with melanoma including preferen-
tially expressed antigen in melanoma (PRAME) and the
tyrosine-related protein-1 (TRP-1). When the melanoma
associated genes were studied alone, PRAME clustered
close to the other MDA believe to be involved in the pig-
mentation process (tyrosinase, MART-1/Melan and
gp100/PMel17). This is of particular interest because
PRAME has been also reported to be highly expressed in
other cancers of ectodermic origin such as medulloblast-
oma and neuroblastoma suggesting a link between ecto-
derm and pigmentation [19,20]. The coordinated
expression of MDA suggests that their down-regulation or
loss of expression during melanoma progression may be
related to a central regulatory pathway not as yet identi-
fied. Indeed in previous studies [21-25], we noted that
loss of expression of MART-1/Melan A paralleled that of
gp100/PMel17 (SILV) in melanoma metastases while
genes of the MAGE family manifested an independent
behavior [25]. This finding may have important repercus-Page 3 of 14
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tocols and at the same time may complicate the
interpretation of tumor antigen loss variant analysis by
broadening loss of expression to antigens other than those
targeted by a given therapy.
Immunological Signature
The large majority of genes associated with immune func-
tion were included in cluster e. These genes appeared up-
regulated in lymph node metastases of melanoma as well
as those from colorectal primaries suggesting that their
expression results from lymphoid cell infiltration (Figure
3). The same genes were up-regulated in a significant pro-
portion of subcutaneous melanoma metastases suggest-
ing that a strong and active infiltrate of immune cells is
present in these tissues. In fact, most of the genes included
in cluster e were significantly up-regulated in 10 cutane-
ous/subcutaneous melanoma lesions compared to 70 pri-
mary cancers of other histology (Table 3 shows a selection
of the most significantly up-regulated genes in cutaneous/
subcutaneous melanomas). Of interest is the observation
that several of the genes up-regulated in these lesions are
clustered in specific chromosomal locations with a high
predominance of genes located in position 6p21.3,
11p11.2, 19p13 and 19q13. Among the immunologi-
cally-related genes specifically up-regulated in
subcutaneous melanoma metastases, some are of particu-
lar interest because of their known relationship with effec-
tor T cell function. In particular, we find interesting that
NK4, an anti-angiogenic factor released by natural killer
cells [26], was constitutively expressed by cutaneous
melanomas. We found this gene to be associated with
regression of a melanoma metastasis during interleukin-2
therapy [27] and to be one of the genes most frequently
up-regulated during activation of antigen-specific T cells
in vitro [28,29]. Of interest was also the constitutive
expression of CD27 a co-stimulatory member of the TNF
receptor family strongly associated with cell activation
[30,31]. The expression of CX3CR1 a gene constitutively
expressed by natural killer cells that makes them sensitive
to chemo-attraction by CXCL12 and CXC3L1 [32] may be
an explanation for a preferential localization of these
effector cells in melanoma lesions. In particular, this find-
ing suggests that the microenvironment of melanoma
metastases is rich of fractalkine (CX3CL1) which is a
potent chemo-attractant released by endothelial cells
stimulated by interferons [33]. Overall, the presence of
these and other (KLRG1; killer cell lectin like receptor sub-
family G, member 1 and KLRK1; killer cell lectin like
receptor subfamily K, member 1 and the interleukin-21
receptor) natural killer cell-related genes suggests potent
chemo-attraction toward natural killer cells by the tumor
micro-environment of subcutaneous and cutaneous
melanoma metastases. This is also emphasized by the
high expression of interleukin-21 receptor which is usu-
ally expressed by natural killer cells and stimulates their
cytolytic activity upon ligation with interleukin-21 pro-
duced by activated T cells [34,35]. The constitutive expres-
sion of interferon regulatory factor (IRF)-7 implicated in
the amplification of the innate immune response [36]
through interactions with the NF-κB pathway [37] may
lead to the activation of various types of type I interferons
Table 1: Samples used for the analysis presented in the same ordered displayed in the supervised analyses.
Histology Location # of Specimens Source
RCC Primary 14 Mainz University, Germany
Melanoma Primary 1 Padua University, Italy
Melanoma In Transit Metastases 3 Padua University, Italy
Melanoma Cutaneous Metastases 7 Padua University, Italy
Melanoma Lymph Node Metastasis 35 Padua University, Italy
Melanoma Visceral Metastases 2 Padua University, Italy
Melanoma Cutaneous Metastases (FNA) 21 NCI, NIH, Bethesda, USA
EOC Primary 15 MD Anderson CC, Houston, TX, USA
Soft Tissue Sarcoma Primary 3 Tissue Network, Philadelphia, PA, USA
Endometrial Cancer Primary 1 Tissue Network, Philadelphia, PA, USA
Laryngeal Cancer Primary 1 Tissue Network, Philadelphia, PA, USA
Breast Cancer Primary 2 Tissue Network, Philadelphia, PA, USA
Colon Adeno-Carcinoma Primary 1 Tissue Network, Philadelphia, PA, USA
Esophageal Carcinoma Primary 12 NCI, NIH, Bethesda, USA,
Colorectal Carcinoma Primary 35 University of Pisa, Italy
Colorectal Carcinoma Lymph Node Metastasis 16 University of Pisa, Italy
Colorectal Carcinoma Hepatic Metastasis 1 University of Pisa, Italy
Total Specimens 180
RCC = Renal Cell Carcinoma; FNA = Fine Needle Aspirates; EOC = Epithelial Ovarian Cancer;Page 4 of 14
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leukin-16, a pleiotropic cytokine with predominant
chemo-attractant activity for CD4+ T cells [39] and CD4+
eosinophils [40]; a relationship between this cytokine and
melanoma metastases has never been observed before. In
summary, the immunological signature portrayed by sub-
cutaneous melanoma metastases is that of an active innate
immune response centered on natural killer cells. More
broadly, the preferential expression of genes with
immune function in melanoma lesions compared with
other tumors suggests that this cancer is constitutively
immunologically active and this status may predispose
metastatic melanoma to respond to general or antigen-
specific immune manipulation.
A second and smaller group of immunologically-related
genes was identified and included genes that segregated
separately in clusters f to j. These genes had an expression
Eisen's clustering based on 2,044 genes up-regulated in metastatic melanoma lesions compared with all other tumorsFigure 1
Eisen's clustering based on 2,044 genes up-regulated in metastatic melanoma lesions compared with all other tumors. Signa-
tures include growth regulation (maroon vertical bar); a signature of genes similarly expressed by melanoma and RCC (blue 
vertical bar) including a sub-cluster of genes predominantly expressed by RCC (double vertical blue bar and blue arrow); an 
immunological signature (orange vertical bar); a signature specific for genes predominantly expressed by cutaneous and subcu-
taneous melanoma metastases (green vertical bar); gene related to blood contamination in fine needle aspirates (FNA; red 
arrow) and a signature specific for melanoma differentiation antigens (MDA; blue arrow). Genes were identified by a two-tailed 
Student's t test comparing all melanoma lesions with other tumors (with the exception of RCC) applying as cut off of signifi-
cance a p2-value < 0.001. Up-regulation was defined as a positive value after subtracting the average of other tumor samples 
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included in cluster e and appeared over-expressed in sub-
cutaneous compared to lymph node metastases. Two
granzyme-related genes were found strongly up-regulated
in cluster e including granzyme A and M. This observa-
tion contrasted with the increased expression of cathepsin
F and L in cluster f to j suggesting an opposite regulation
of these genes involved in cell death or survival.
Subcutaneous metastases-associated genes
It has been reported that subcutaneous metastases of
melanoma are more responsive to immunotherapy with
interleukin-2 than lymph nodal and visceral metastases
[16]. Therefore, we identified genes differentially
expressed in the former compared with the latter. Since no
material from visceral metastases was available, we lim-
ited the comparison to subcutaneous versus lymph nodal
metastases. Overall, clusters g - j appeared to demonstrate
a preferential expression of genes in subcutaneous metas-
tases independent of the technique used for biopsy (exci-
sion versus FNA). In particular, cluster g contained a
small node of 47 clones highly expressed in subcutaneous
metastases that included PRAME and TRP-1. This cluster
also included the renal tumor antigen RAGE which has
been previously shown to be highly expressed by melano-
mas [41] and melanophilin and the s100 protein often
associated with clinical parameters in melanoma [42].
Interestingly, closely linked to PRAME was the pattern of
expression of the serine/threonine-specific protein kinase
B-RAF. This gene is mutated in approximately 70 % of
melanomas and it is often over-expressed [43]. Although
several of these genes had been associated with melanoma
their co-ordinate expression has never been previously
appreciated. Overall, the identity of the genes over-
expressed in subcutaneous metastases did not offer an
obvious explanation for the increased immune
responsiveness of these lesions and more extensive under-
standing of their relationship will be necessary in the
future.
Genes differential expressed by melanoma and RCC 
samples compared with other solid tumors
We then pooled together melanoma and RCC samples
data to identify genes commonly expressed by these
tumors and not by tumors of other histology. Significance
was assessed by a two-tailed unpaired student's t test and
identified 4,221 genes at a cut off p2-value of ≤ 0.001. The
data set was then filtered using the Cluster Program (Stan-
ford, CA) selecting genes that were expressed in at least 80
% of the experiments and for which a Cy5/Cy3 log2 ratio
Table 2: Genes of known association with melanoma
Clone ID Chromosomal Location Name AVERAGE t-test (p2-value)
RCC MEL Other RCC vs MEL MEL vs Other
Cluster a
2569910 Xp11.2 MAGED2 -0.22 0.4 -0.28 7.10E-03 8.00E-07
316397 Xp11.2 MAGED2 -0.24 0.41 -0.29 5.60E-04 3.00E-07
P24478 Xp11.2 MAGED2 -0.21 0.31 -0.22 5.10E-03 1.00E-06
Cluster d
1735474 Xq26 MAGEC1 0.03 0.25 -0.26 3.40E-02 6.80E-06
131595 Xq28 MAGEA10 -0.03 0.28 -0.24 6.20E-02 1.80E-04
1505360 Xq28 MAGEA2 -0.88 0.94 -0.76 6.00E-12 2.00E-10
Cluster e
781233 2p23.3 POMC -0.03 0.17 -0.15 2.20E-01 1.40E-05
Cluster g
897956 22q11.22 PRAME -0.62 1.33 -1.05 1.60E-06 1.00E-18
853789 9p23 TYRP1 -0.82 0.59 -0.3 7.70E-06 8.00E-04
768344 9p23 TYRP1 -0.7 0.8 -0.61 1.60E-07 1.80E-06
40056 15q23 CSPG4 -0.32 0.69 -0.53 2.20E-04 2.70E-09
P07338 n.a. CSPG4 -0.63 0.78 -0.61 8.50E-05 5.70E-09
2447688 11q23.3 MCAM 0.21 0.69 -0.6 8.70E-02 3.40E-09
1585510 3q28-q29 MFI2 (p97) -0.48 0.59 -0.44 1.10E-03 5.70E-07
Cluster i
P30563 n.a. CD63 -0.66 0.7 -0.44 8.20E-08 1.90E-09
1631546 Xq28 MAGEA6 -0.55 0.35 -0.22 1.30E-08 5.60E-04
291448 12q13-q1 SILV (gp100) -1.31 1.55 -1.16 4.90E-16 5.00E-15
271985 11q14-q2 || TYR Tyrosinase -1.37 1.73 -1.38 6.30E-18 2.90E-18
272327 9p24.1 Melan-A -0.76 1.19 -0.95 2.40E-08 1.80E-16
269124 9p24.1 Melan-A -0.65 1.21 -0.99 5.30E-09 2.70E-16Page 6 of 14
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eight hundred and forty-three genes resulted from this fil-
ter. Because of the predominance of melanoma lesions
(69 melanoma lesions compared to 14 RCC) the genes
identified strongly represent differences between melano-
mas and other tumors. Therefore, we identified among
them those that were not differentially expressed between
melanoma and RCC samples to identify those genes that
are truly uniquely expressed by the two immune respon-
sive cancers. Two-thousand three hundred and fifty-eight
genes were expressed similarly between the two types of
cancer (at a t test p2-value > 0.05). A significant number of
genes commonly expressed by melanoma and RCC and
not by other tumors had no known function (681 genes).
The remaining 1, 677 genes were further analyzed by sep-
arating those up-regulated from those down-regulated in
melanoma and RCC compared with other tumors. The
genes up-regulated in RCC and melanoma were consid-
ered those with a median LogRatio above 0.3 in either RCC
or melanomas (a selection of these genes is shown in
Table 4). This analysis selected 199 genes. A proportion of
genes appeared to be specifically related to lymph nodal
and immune infiltration as they were particularly up-reg-
ulated in melanoma metastases to lymph nodes and in
Eisen's clustering of genes already reported to be preferentially expressed by melanomasFigure 2
Eisen's clustering of genes already reported to be preferentially expressed by melanomas. The analysis was performed on 180 
cancer samples as described in the Results section and ordered according to Table 1. In particular, renal cell cancer (RCC, 
orange), melanoma (blue), Epithelial Ovarian Cancer (EOC, yellow), Esophageal Cancer (green), Primary Colorectal Cancer 
(CRC, dark brown) and lymph nodal metastases of CRC (light brown) are shown. Melanoma samples are further subdivided in 
cutaneous metastases (CM, light blue) from frozen sections (continuous line) or fine needle aspirates (FNA, dashed line) and 
lymph nodal metastases (LN, darker blue line). Below is the distance among the various genes based on Eisen's clustering.
RCC Melanoma EOC Esophageal CRC Primary CRC Lymph Nodes
CM LN CM (FNA)Page 7 of 14
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(orange vertical bar, Figure 4). These genes included
annotations related to immunological function. A set of
genes was specifically expressed in cutaneous metastases
of melanoma and in RCC and not other tumor samples
(dark blue vertical bar, Figure 4). These genes included
microphtalmia transcription factor MITF [17,44]. that has
been shown previously to exert a central role in the regu-
lation of transcriptional activity of melanoma cells. Simi-
larly, enolase-2 (previously known to be up-regulated in
RCC) [11] was found to be over-expressed in common
between the two histologies. This is somewhat surprising
since immunohistochemical analysis has used lack of
staining for enolase-2 as a reliable method to differentiate
malignant melanoma (enolase-2 negative) from Merkel
cell carcinoma [45]. It is possible, that although identifia-
ble at the transcriptional level, enolase-2 is not processed
into a protein in melanomas. On the other hand, enolase-
2 has been shown to be expressed in approximately 90 %
of canine oral melanomas [46]. In addition, the macro-
phage migration inhibiting factor (MIF) which is a modu-
lator of cell cycle progression and angiogenesis in
melanoma [47,48]. was found co-expressed by melanoma
and RCC lesions. MIF has modulatory properties on nat-
ural killer cell mediated lysis of cancer cells contributing,
therefore, to an immune privileged microenvironment in
uveal melanoma [49]. Two genes coding for adhesion
molecules; L1 cell adhesion molecule (LCAM) and
melanoma cell adhesion molecule (MCAM) were also up-
regulated in both lesions and may play an important role
in mediating migration of immune cells to the tumor
deposits [50]. Finally, it is remarkable that serologically
Eisen's clustering of immunologically relevant genes selected from clusters e and f-jFigure 3
Eisen's clustering of immunologically relevant genes selected from clusters e and f-j. To the right the identity of the genes 
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Clone ID Location Gene AVERAGE t-test (p2-value)
SQ Other SQ vs Oth Me vs Oth
295868 1p34 LAPTM5 0.43 -0.68 2.00E-04 3.00E-04
P37265 1p34.3 LCK 0.55 -0.58 1.00E-04 6.00E-06
2563224 1p36.2 PIK3CD 0.8 -0.88 3.00E-07 5.00E-15
842871 1q12 PDE4DIP 0.58 -0.21 5.00E-04 9.00E-05
773509 1q21.3 SNX27 1.05 -0.88 9.00E-11 7.00E-16
701332 1q22 IFI16 0.25 -0.39 2.00E-04 1.00E-05
472009 1q42.1 DISC1 0.35 -0.26 1.00E-07 9.00E-08
746229 2q11.2-q MAP4K4 0.15 -0.24 7.00E-04 6.00E-05
840466 2q12-q13 MARCO 0.34 -0.28 3.00E-05 2.00E-04
328542 2q24-q3 GALNT3 0.51 -0.4 4.00E-04 1.00E-03
825715 2q37.1 SP110 0.71 -0.59 9.00E-07 3.00E-09
283023 3p21 CX3CR1 0.31 -0.34 2.00E-05 4.00E-10
1605539 4p16.3 IDUA 0.27 -0.29 4.00E-06 6.00E-06
724932 5q35 GRK6 0.43 -0.19 4.00E-05 3.00E-05
753587 6p21.3 BTN3A3 0.49 -0.43 2.00E-05 5.00E-06
753236 6p21.3 TAP2 0.31 -0.42 2.00E-04 1.00E-07
752557 6p21.3 GPSM3 0.42 -0.42 1.00E-04 3.00E-06
2549448 6q21 FYN 0.6 -0.45 1.00E-07 2.00E-07
2306953 8q13.3 LY96 1.01 -0.32 3.00E-06 2.00E-08
645332 10p12 NEBL 0.23 -0.23 6.00E-04 2.00E-04
1631391 11p11.2 BHC80 0.35 -0.29 8.00E-04 4.00E-04
686164 11p11.2 DGKZ 0.44 -0.21 2.00E-04 4.00E-04
487115 11p11.2 PTPRJ 0.78 -0.4 3.00E-09 5.00E-07
151430 11p13 CD44 0.71 -0.22 1.00E-03 2.00E-05
740117 11p15.5 IRF-7 0.53 -0.3 4.00E-05 3.00E-04
P33303 11p15.5 LSP1 0.55 -0.4 1.00E-03 2.00E-05
1850690 11q23.3 BLR1 0.36 -0.36 6.00E-05 2.00E-04
2120815 12p12-p1 KLRG1 0.51 -0.44 1.00E-04 5.00E-04
34637 12p13 CD27 0.72 -0.54 4.00E-04 1.00E-04
1517162 12p13.2- KLRK1 0.55 -0.53 5.00E-04 6.00E-04
1569551 12q13.11 CSAD 0.37 -0.45 2.00E-04 6.00E-06
429186 13q21.33 LMO7 0.41 -0.37 5.00E-06 4.00E-19
P41256 15q26.3 IL-16 0.64 -0.58 4.00E-05 2.00E-06
P14913 16p11 IL-21R1 0.48 -0.43 6.00E-06 6.00E-04
P07382 16p11.2 ITGAL 0.55 -0.48 2.00E-05 3.00E-06
P12753 16p13.3 NK4; 0.32 -0.3 4.00E-05 3.00E-06
206795 17p ASGR2 0.57 -0.53 8.00E-05 6.00E-06
488575 17p11.2 ULK2 0.35 -0.17 3.00E-06 1.00E-04
155717 17q23 CD79B 0.44 -0.41 3.00E-05 2.00E-11
156343 17q24.2 MAP3K3 0.62 -0.46 4.00E-06 7.00E-11
P38436 17q25 CARD14 0.54 -0.33 4.00E-08 2.00E-08
1551273 19p12 MEF2B 0.19 -0.21 7.00E-05 1.00E-09
814377 19p13.1 BRD4 0.9 -0.7 6.00E-06 2.00E-16
2010562 19p13.3 MYO1F 0.55 -0.62 9.00E-04 7.00E-05
824384 19p13-q1 CD37 0.64 -0.74 1.00E-03 7.00E-04
788272 19q13.1 CLC 0.61 -0.64 7.00E-06 3.00E-06
815239 19q13.13 ARHGEF1 0.38 -0.42 3.00E-05 1.00E-04
683276 19q13.33 CARD8 0.86 -0.64 1.00E-08 3.00E-05
277906 19q13.4 LILRB1 0.89 -0.51 4.00E-04 5.00E-04
202897 19q13.4 LILRB2 0.72 -0.61 4.00E-04 1.00E-06
2072768 20q12 NCOA3 0.69 -0.36 4.00E-06 2.00E-05
SQ = Average Cy5/Cy3 ratios of10 frozen samples from cutaneous and subcutaneous metastases as described in Table I. Oth = Sample from 80 
primary tumors other than melanoma and RCC with the exclusion, in this table of lymph nodal metastases from colorectal cancer (see Table I). 
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by melanoma and RCC while was completely absent in
colon cancers underlying the need for a better nomencla-
ture of newly identified genes.
This is a descriptive study where genes specifically
expressed by melanoma metastases were identified com-
paring a large collection of samples from patients with
metastatic cutaneous melanoma with other primary
tumors and lymph nodal metastases. A limitation of the
study is the lack of other samples including visceral metas-
tases of melanoma and metastases from tumors of other
histology. Nevertheless, we considered useful to compile
a list of genes characteristically expressed by subcutaneous
and lymph nodal lesions of melanoma for reference
purposes and we are willing to provide full information
about these genes upon request. In spite of the limitations
of this study, few general conclusions could be drawn.
Materials and Methods
Tissue procurement
Fourteen primary renal cell carcinoma (RCC) specimens
were collected at the Department of Urology of The Johan-
nes Gutenberg-University, Mainz, Germany; one primary
Table 4: Selected genes constitutively expressed by RCC and melanoma metastases.
UNIQID NAME Extended Name Median log2Cy5/Cy3 Averagelog2Cy5/Cy3 t-test*
RCC MEL OTH RCC MEL OTH p2-value
274276 IFIT2 interferon-induced protein with tetratricopeptide repeats 2 0.74 0.30 -0.28 0.54 0.18 -0.23 0.06
191173 ITGB7 integrin, beta 7 0.17 0.33 -0.26 0.14 0.30 -0.26 0.51
191169 FLT3LG fms-related tyrosine kinase 3 ligand 0.18 0.32 -0.27 0.31 0.19 -0.20 0.53
187264 CORO1A coronin-like protein p57=actin binding protein p57 0.38 0.13 -0.19 0.47 0.12 -0.17 0.16
189684 SP110 SP110 nuclear body protein 0.22 0.60 -0.56 0.26 0.44 -0.42 0.27
279561 TNFRSF7 CD27 -0.06 0.65 -0.39 -0.09 0.45 -0.35 0.07
279871 CD37 CD37 antigen 0.09 0.56 -0.56 0.33 0.47 -0.38 0.72
276143 TAP2 transporter 2 0.23 0.33 -0.21 0.27 0.31 -0.24 0.86
281103 sialic acid binding Ig-like lectin 7=D-siglec=expressed in dendritic 
cells
0.33 0.26 -0.34 0.27 0.24 -0.24 0.86
279699 BTK btk = Bruton agammaglobulinemia tyrosine kinase || -0.04 0.45 -0.28 -0.09 0.34 -0.26 0.05
274604 CST7 cystatin F (leukocystatin) || -0.14 0.37 -0.29 -0.07 0.45 -0.34 0.06
281440 ITGB7 CD103 beta=Integrin beta 7 || 0.36 0.39 -0.25 0.31 0.38 -0.35 0.67
191157 KLRG1 killer cell lectin-like receptor subfamily G, member 1 || 0.32 0.40 -0.17 0.35 0.23 -0.25 0.39
274016 RASGRP1 RAS guanyl releasing protein 1 (calcium and DAG-regulated) || 0.48 0.38 -0.29 0.36 0.30 -0.29 0.78
274444 ITGAL integrin, alpha L (antigen CD11A (p180)| 0.34 0.57 -0.43 0.30 0.33 -0.31 0.88
282504 CX3CR1 chemokine (C-X3-C motif) receptor 1 0.84 0.66 -0.53 0.62 0.51 -0.50 0.76
274267 KLRK1 killer cell lectin-like receptor subfamily K, member 1 0.80 0.33 -0.20 0.71 0.34 -0.38 0.14
187290 LILRB1 LIR-7=PIR homologue| 0.11 0.67 -0.15 0.12 0.49 -0.41 0.20
186380 SLC2A3 solute carrier family 2 (facilitated glucose transporter), member 3 0.14 0.34 -0.21 0.34 0.36 -0.34 0.94
188111 CD3Z CD3Z antigen, zeta polypeptide (TiT3 complex) 0.09 0.42 -0.30 -0.01 0.35 -0.27 0.10
186528 SLA SLAP=src-like adapter protein 0.38 0.31 -0.24 0.32 0.33 -0.31 0.98
185279 ASGR2 asialoglycoprotein receptor 2| 0.28 0.61 -0.33 0.17 0.45 -0.40 0.16
187450 LILRB2 leukocyte immunoglobulin-like receptor, subfamily B, member 2 0.10 0.65 -0.45 0.13 0.54 -0.44 0.07
184382 FGR Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog| 0.57 0.23 -0.29 0.40 0.27 -0.28 0.49
190623 MYO1F myosin IF| 0.18 0.50 -0.22 0.16 0.46 -0.38 0.24
188800 PILRA paired immunoglobin-like type 2 receptor alpha 0.16 0.56 -0.08 0.07 0.31 -0.27 0.17
188004 CLC Charcot-Leyden crystal protein| 0.08 0.51 -0.33 0.08 0.53 -0.44 0.08
186399 PPP3CC protein phosphatase 3, catalytic subunit, gamma isoform 
(calcineurin A gamma)|
0.07 0.36 -0.15 0.05 0.21 -0.18 0.17
278997 XLHSRF-1 heat shock regulated 1 -0.12 0.32 -0.09 0.10 0.28 -0.20 0.33
281827 LLT1 lectin-like NK cell receptor 0.46 0.26 -0.33 0.53 0.22 -0.26 0.08
282466 LLT1 lectin-like NK cell receptor 0.22 0.38 -0.23 0.23 0.32 -0.32 0.66
189527 FMNL1 formin-like 1 0.46 0.43 -0.25 0.44 0.24 -0.26 0.32
282550 natural killer cell transcript 4 -0.20 0.41 -0.29 0.00 0.30 -0.24 0.15
282534 B-cell CLL/lymphoma 2 0.05 0.38 -0.38 -0.05 0.33 -0.34 0.05
282477 ICOS inducible T-cell co-stimulator| -0.07 0.37 -0.18 -0.07 0.28 -0.26 0.07
282624 granzyme A granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated 
serine esterase 3)|
-0.10 0.58 -0.33 -0.16 0.43 -0.31 0.06
* Two-tailed un-paired t test between RCC and MEL samples. RCC = Renal cell carcinoma; Mel = melanoma lesions; Oth = all other tumors in the 
study (see Table I).Page 10 of 14
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metastases, thirty-five lymph nodal metastases and two
visceral metastases of cutaneous melanoma were collected
at the Department of Surgical Sciences, University of
Padua, Italy; twenty-one fine needle aspirates of cutane-
ous melanoma metastases were obtained at the Surgery
Branch, National Cancer Institute, National Institutes of
Health, Bethesda, MD; seventeen primary epithelial
ovarian cancer (EOC) specimens were obtained at the
Department of Gynecologic Oncology, MD Anderson
Cancer Center, TX; three primary sarcoma, one primary
endometrial cancer, one primary laryngeal cancer, two
primary breast cancers and one primary colon adeno-car-
cinoma were obtained from the Tissue Network (Philadel-
phia, PA); twelve primary carcinomas of the esophageal
junction were obtained from the NCI (Division of Cancer
Treatment and Diagnosis); thirty-five primary, 16 lymph
node metastases and one hepatic metastasis from colorec-
tal adeno-carcinomas were obtained from the Depart-
ment of Pathology of the University of Pisa, Italy.
Specimens were collected as the result of routine operative
procedures and portions were frozen for subsequent anal-
ysis while the remnant tissue was used for pathological
confirmation. Tissue procurement followed standard eth-
ical procedure according to institutional policy. A sum-
mary of the specimens studied is presented in Table 1 with
their order reflecting their distribution in figures where
supervised analyses are shown.
Eisen's clustering of genes similarly expressed by RCC and melanoma lesionFigure 4
Eisen's clustering of genes similarly expressed by RCC and melanoma lesion. To the right the identity of genes most promi-
nently expressed by RCC lesions and cutaneous or subcutaneous melanoma lesions is shown.
RCC Melanoma EOC Esophageal CRC Primary CRC Lymph Nodes
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Total RNA was extracted from frozen material using Trizol
reagent according to manufacturer's instructions (Invitro-
gen, CA) and amplified into anti-sense RNA (aRNA) as
previously described [10,27,51,52]. Although the quan-
tity of starting total RNA was in most cases sufficient for
cDNA array hybridization, we have shown repeatedly that
the fidelity of aRNA hybridization is at least equal and
likely superior to total RNA for transcriptional profiling
due to lack of contaminant ribosomal and transfer RNA
[51,53]. Therefore, we used aRNA to increase consistency
of results particularly when low quality total RNA was
documented by Agilent Bioanalyzer 2000 (Agilent Tech-
nologies, Palo Alto, CA). After amplification the quality of
aRNA was tested with the Agilent Bioanalyzer as previ-
ously described [52].
Total RNA from peripheral blood mononuclear cells
pooled from six normal donor was extracted and ampli-
fied to serve as constant reference as previously described
[10,27,51,52]. Test and reference RNA were labeled with
Cy5 (red) and Cy3 (green) and co-hybridized to a costum-
made17.5 K cDNA micro-array http://nci
array.nci.nih.gov/gal_files/index.shtml. Micro-arrays were
printed at the Immunogenetics Section, DTM, CC, NIH
with a configuration of 32 × 24 × 23 and contained
17,500 elements. Clones used for printing included a
combination of the Research Genetics RG_HsKG_031901
8 k clone set and 9,000 clones selected from the
RG_Hs_seq_ver_070700 40 k clone set. The 17,500 spots
included 12,072 uniquely named genes, 875 duplicated
genes and about 4,000 expression sequence tags.
Data analysis
All statistical analyses were performed using the log2-
based ratios normalizing the medial log2 ratio value across
the array equal to zero. Validation and reproducibility
were performed using our internal reference concordance
system as previously described [54]. Unsupervised
clustering was performed according to the Eisen's Pearson
correlation method [55] and visualized with Tree-View
software (Stanford University, CA). Genomic portraits
were depicted according to the central method for display
using a normalization factor as suggested by Ross et al.
[56]. Details about different tests are discussed in the
respective results section. Identification of tumor-specific
genes was performed using un-paired 2-tailed Student's t
test. The same analyses were performed using un-paired
Wilcoxon's non-parametric assessment and provided the
same conclusions (not shown). Details of each analysis
are presented in the results section.
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